A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe, Semi-Immune, Healthy Adults 18 to 45 Years of Age.

Trial Profile

A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe, Semi-Immune, Healthy Adults 18 to 45 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs Malaria vaccine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top